Chinese biopharmaceutical startup Gracell Biotechnologies Co., Ltd recently announced the completion of a US$100 million Series C financing. This round of financing was led by Wellington Management Company, OrbiMed and Morningside Ventures.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
